Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Gubra – Presentation of Q2 report 2023

By HC Andersen Capital
Gubra

Meet and ask questions to Gubra’s CEO Henrik Blou and CFO Kristian Borbos on 28 August at 10.00 am CEST when they present the Q2 report 2023 and the latest development.

Gubra has two divisions CRO and D&P, and late in the quarter the company acquired a research service provider MiniGut ApS to the CRO division.

Gubra, founded in 2008 in Denmark, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. See www.gubra.dk for more information. Gubra is listed on Nasdaq Copenhagen mid Cap, with ticker code GUBRA.

Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 14:30, 05-07-2023.

Recent videos

GomSpace - Strategic direction & Q&A
19.01.2026 klo 15.00 GomSpace Group
Oncopeptides, Audiocast, Investor Conference, 2026
16.01.2026 klo 10.00 Oncopeptides
Duell, Webcast, Q1'26
14.01.2026 klo 10.30 Duell
Dustin Group, Audiocast, Q1'26
14.01.2026 klo 10.00 Dustin Group
Herantis Pharma Plc, Phase 1b biomarker data webcast
08.01.2026 klo 12.00 Herantis Pharma
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.